Cycloserine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cycloserine" in English language version.

Last modified: 04:10:33, 11 August 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

4025nih.gov

5^th place

3221doi.org

2^nd place

112drugs.com

529^th place

550^th place

72semanticscholar.org

15^th place

8^th place

64web.archive.org

1^st place

44adsabs.harvard.edu

14^th place

9^th place

42worldcat.org

4^th place

32nytimes.com

7^th place

22hdl.handle.net

66^th place

34^th place

21netfirms.com

9,451^st place

4,978^th place

21openlibrary.org

185^th place

154^th place

11books.google.com

3^rd place

11who.int

213^th place

314^th place

11patents.google.com

1,154^th place

606^th place

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

ui.adsabs.harvard.edu

Silverman R (1998). "An Aromatization Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase for the Antibiotic l-Cycloserine". Journal of the American Chemical Society. 120 (10): 2256–2267. Bibcode:1998JAChS.120.2256O. doi:10.1021/ja972907b.
Kuehl Jr FA, Wolf FJ, Trenner NR, Peck RL, Buhs RP, Howe E, et al. (1955). "D-4-Amino-3-isoxazolidinone, a new antibiotic". Journal of the American Chemical Society. 77 (8): 2344–2345. Bibcode:1955JAChS..77.2344K. doi:10.1021/ja01613a105.
Hidy PH, Hodge EB, Young VV, Harned RL, Brewer GA, Phillips WF, et al. (1955). "Synthesis of D-4-amino-3-isoxazolidinone". Journal of the American Chemical Society. 77 (8): 2346–2347. Bibcode:1955JAChS..77.2346S. doi:10.1021/ja01613a107.
Hidy PH, Hodge EB, Young VV, Harned RL, Brewer GA, Phillips WF, et al. (1955). "Structure and reactions of cycloserine". Journal of the American Chemical Society. 77 (8): 2345–2346. Bibcode:1955JAChS..77.2345H. doi:10.1021/ja01613a106.

books.google.com (Global: 3^rd place; English: 3^rd place)

Gottlieb D, Shaw PD (2012). Mechanism of Action. Springer Science & Business Media. p. 41. ISBN 978-3-642-46051-7. Archived from the original on 2016-12-20.

doi.org (Global: 2^nd place; English: 2^nd place)

Nitsche MA, Jaussi W, Liebetanz D, Lang N, Tergau F, Paulus W (August 2004). "Consolidation of human motor cortical neuroplasticity by D-cycloserine". Neuropsychopharmacology. 29 (8): 1573–1578. doi:10.1038/sj.npp.1300517. PMID 15199378.
Sapko MT, Manyak M, Panicucci R, Javitt JC (March 2024). "NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro". Antibiotics. 13 (4). National Institutes of Health: 308. doi:10.3390/antibiotics13040308. PMC 11047644. PMID 38666984.
Lambert MP, Neuhaus FC (June 1972). "Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W". Journal of Bacteriology. 110 (3): 978–987. doi:10.1128/JB.110.3.978-987.1972. PMC 247518. PMID 4555420.
Prosser GA, de Carvalho LP (February 2013). "Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine". The FEBS Journal. 280 (4): 1150–1166. doi:10.1111/febs.12108. PMID 23286234. S2CID 22305408.
Schade S, Paulus W (April 2016). "D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review". The International Journal of Neuropsychopharmacology. 19 (4) pyv102. doi:10.1093/ijnp/pyv102. PMC 4851259. PMID 26364274.
Polc P, Pieri L, Bonetti EP, Scherschlicht R, Moehler H, Kettler R, et al. (April 1986). "L-cycloserine: behavioural and biochemical effects after single and repeated administration to mice, rats and cats". Neuropharmacology. 25 (4). Elsevier BV: 411–418. doi:10.1016/0028-3908(86)90236-4. PMID 3012401. S2CID 462885.
Wood JD, Peesker SJ, Gorecki DK, Tsui D (February 1978). "Effect of L-cycloserine on brain GABA metabolism". Canadian Journal of Physiology and Pharmacology. 56 (1): 62–68. doi:10.1139/y78-009. PMID 638858.
Kaushal G, Ramirez R, Alambo D, Taupradist W, Choksi K, Sirbu C (October 2011). "Initial characterization of D-cycloserine for future formulation development for anxiety disorders". Drug Discoveries & Therapeutics. 5 (5): 253–260. doi:10.5582/ddt.2011.v5.5.253. PMID 22466372.
Silverman R (1998). "An Aromatization Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase for the Antibiotic l-Cycloserine". Journal of the American Chemical Society. 120 (10): 2256–2267. Bibcode:1998JAChS.120.2256O. doi:10.1021/ja972907b.
Holt GR (1986). "Principles of Plastic Surgery of Congenital Facial Abnormalities". Facial Plastic Surgery. 3 (03): 147–154. doi:10.1055/s-2008-1064836. PMID 3459696.
Uda N, Matoba Y, Kumagai T, Oda K, Noda M, Sugiyama M (June 2013). "Establishment of an in vitro D-cycloserine-synthesizing system by using O-ureido-L-serine synthase and D-cycloserine synthetase found in the biosynthetic pathway". Antimicrobial Agents and Chemotherapy. 57 (6): 2603–2612. doi:10.1128/AAC.02291-12. PMC 3716191. PMID 23529730.
Kuehl Jr FA, Wolf FJ, Trenner NR, Peck RL, Buhs RP, Howe E, et al. (1955). "D-4-Amino-3-isoxazolidinone, a new antibiotic". Journal of the American Chemical Society. 77 (8): 2344–2345. Bibcode:1955JAChS..77.2344K. doi:10.1021/ja01613a105.
Hidy PH, Hodge EB, Young VV, Harned RL, Brewer GA, Phillips WF, et al. (1955). "Synthesis of D-4-amino-3-isoxazolidinone". Journal of the American Chemical Society. 77 (8): 2346–2347. Bibcode:1955JAChS..77.2346S. doi:10.1021/ja01613a107.
Hidy PH, Hodge EB, Young VV, Harned RL, Brewer GA, Phillips WF, et al. (1955). "Structure and reactions of cycloserine". Journal of the American Chemical Society. 77 (8): 2345–2346. Bibcode:1955JAChS..77.2345H. doi:10.1021/ja01613a106.
Ori R, Amos T, Bergman H, Soares-Weiser K, Ipser JC, Stein DJ (May 2015). "Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders". The Cochrane Database of Systematic Reviews. 2015 (5) CD007803. doi:10.1002/14651858.CD007803.pub2. PMC 8939046. PMID 25957940.
Myers KM, Carlezon WA (June 2012). "D-cycloserine effects on extinction of conditioned responses to drug-related cues". Biological Psychiatry. 71 (11): 947–955. doi:10.1016/j.biopsych.2012.02.030. PMC 4001849. PMID 22579305.
Mataix-Cols D, Fernández de la Cruz L, Monzani B, Rosenfield D, Andersson E, Pérez-Vigil A, et al. (May 2017). "D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data". JAMA Psychiatry. 74 (5): 501–510. doi:10.1001/jamapsychiatry.2016.3955. hdl:2066/174490. PMID 28122091. (Erratum: doi:10.1001/jamapsychiatry.2017.0144, PMID 28297011)
Steele DW, Kanaan G, Caputo EL, Freeman JB, Brannan EH, Balk EM, et al. (December 2024). "Treatment of Obsessive-Compulsive Disorder in Children and Youth: A Meta-Analysis". Pediatrics. 155 (3). doi:10.1542/peds.2024-068992. PMID 39639456.
DeMayo MM, Watson M, Harris AD, McGirr A (May 2025). "Serum levels of D-cycloserine predict antidepressant effects in pharmacologically enhanced intermittent theta-burst stimulation". Journal of Affective Disorders. 377: 60–67. doi:10.1016/j.jad.2025.02.062. PMID 39986577.
Cole J, Sohn MN, Harris AD, Bray SL, Patten SB, McGirr A (December 2022). "Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder: A Randomized Clinical Trial". JAMA Psychiatry. 79 (12): 1153–1161. doi:10.1001/jamapsychiatry.2022.3255. PMC 9557938. PMID 36223114.
Schultes RE, Farnsworth NR (1980). "Ethnomedical, Botanical and Phytochemical Aspects of Natural Hallucinogens". Botanical Museum leaflets, Harvard University. 28 (2): 123–214. doi:10.5962/p.168645. ISSN 0006-8098.

drugs.com (Global: 529^th place; English: 550^th place)

"Cycloserine". Drugs.com, The American Society of Health-System Pharmacists. 2024. Retrieved 28 November 2024.
"Cycloserine Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 24 May 2026.

hdl.handle.net (Global: 66^th place; English: 34^th place)

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Mataix-Cols D, Fernández de la Cruz L, Monzani B, Rosenfield D, Andersson E, Pérez-Vigil A, et al. (May 2017). "D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data". JAMA Psychiatry. 74 (5): 501–510. doi:10.1001/jamapsychiatry.2016.3955. hdl:2066/174490. PMID 28122091. (Erratum: doi:10.1001/jamapsychiatry.2017.0144, PMID 28297011)

netfirms.com (Global: 9,451^st place; English: 4,978^th place)

bitnest.netfirms.com

Brimblecombe RW, Pinder RM (1975). "Miscellaneous Hallucinogens". Hallucinogenic Agents. Bristol: Wright-Scientechnica. pp. 196–216. ISBN 978-0-85608-011-1. OCLC 2176880. OL 4850660M. However, the closely related antibiotic oxamycin [(d-cycloserine)] (7.6) produces mental confusion, acute psychotic episodes, convulsions, and other abnormal behavioural states in man reminiscent of the isoxazoles [like muscimol and ibotenic acid] contained in Amanita muscaria (Farnsworth, 1968).

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Nitsche MA, Jaussi W, Liebetanz D, Lang N, Tergau F, Paulus W (August 2004). "Consolidation of human motor cortical neuroplasticity by D-cycloserine". Neuropsychopharmacology. 29 (8): 1573–1578. doi:10.1038/sj.npp.1300517. PMID 15199378.
Sapko MT, Manyak M, Panicucci R, Javitt JC (March 2024). "NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro". Antibiotics. 13 (4). National Institutes of Health: 308. doi:10.3390/antibiotics13040308. PMC 11047644. PMID 38666984.
Lambert MP, Neuhaus FC (June 1972). "Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W". Journal of Bacteriology. 110 (3): 978–987. doi:10.1128/JB.110.3.978-987.1972. PMC 247518. PMID 4555420.
Prosser GA, de Carvalho LP (February 2013). "Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine". The FEBS Journal. 280 (4): 1150–1166. doi:10.1111/febs.12108. PMID 23286234. S2CID 22305408.
Schade S, Paulus W (April 2016). "D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review". The International Journal of Neuropsychopharmacology. 19 (4) pyv102. doi:10.1093/ijnp/pyv102. PMC 4851259. PMID 26364274.
Polc P, Pieri L, Bonetti EP, Scherschlicht R, Moehler H, Kettler R, et al. (April 1986). "L-cycloserine: behavioural and biochemical effects after single and repeated administration to mice, rats and cats". Neuropharmacology. 25 (4). Elsevier BV: 411–418. doi:10.1016/0028-3908(86)90236-4. PMID 3012401. S2CID 462885.
Wood JD, Peesker SJ, Gorecki DK, Tsui D (February 1978). "Effect of L-cycloserine on brain GABA metabolism". Canadian Journal of Physiology and Pharmacology. 56 (1): 62–68. doi:10.1139/y78-009. PMID 638858.
Kaushal G, Ramirez R, Alambo D, Taupradist W, Choksi K, Sirbu C (October 2011). "Initial characterization of D-cycloserine for future formulation development for anxiety disorders". Drug Discoveries & Therapeutics. 5 (5): 253–260. doi:10.5582/ddt.2011.v5.5.253. PMID 22466372.
Holt GR (1986). "Principles of Plastic Surgery of Congenital Facial Abnormalities". Facial Plastic Surgery. 3 (03): 147–154. doi:10.1055/s-2008-1064836. PMID 3459696.
Uda N, Matoba Y, Kumagai T, Oda K, Noda M, Sugiyama M (June 2013). "Establishment of an in vitro D-cycloserine-synthesizing system by using O-ureido-L-serine synthase and D-cycloserine synthetase found in the biosynthetic pathway". Antimicrobial Agents and Chemotherapy. 57 (6): 2603–2612. doi:10.1128/AAC.02291-12. PMC 3716191. PMID 23529730.
Ori R, Amos T, Bergman H, Soares-Weiser K, Ipser JC, Stein DJ (May 2015). "Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders". The Cochrane Database of Systematic Reviews. 2015 (5) CD007803. doi:10.1002/14651858.CD007803.pub2. PMC 8939046. PMID 25957940.
Myers KM, Carlezon WA (June 2012). "D-cycloserine effects on extinction of conditioned responses to drug-related cues". Biological Psychiatry. 71 (11): 947–955. doi:10.1016/j.biopsych.2012.02.030. PMC 4001849. PMID 22579305.
Mataix-Cols D, Fernández de la Cruz L, Monzani B, Rosenfield D, Andersson E, Pérez-Vigil A, et al. (May 2017). "D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data". JAMA Psychiatry. 74 (5): 501–510. doi:10.1001/jamapsychiatry.2016.3955. hdl:2066/174490. PMID 28122091. (Erratum: doi:10.1001/jamapsychiatry.2017.0144, PMID 28297011)
Steele DW, Kanaan G, Caputo EL, Freeman JB, Brannan EH, Balk EM, et al. (December 2024). "Treatment of Obsessive-Compulsive Disorder in Children and Youth: A Meta-Analysis". Pediatrics. 155 (3). doi:10.1542/peds.2024-068992. PMID 39639456.
DeMayo MM, Watson M, Harris AD, McGirr A (May 2025). "Serum levels of D-cycloserine predict antidepressant effects in pharmacologically enhanced intermittent theta-burst stimulation". Journal of Affective Disorders. 377: 60–67. doi:10.1016/j.jad.2025.02.062. PMID 39986577.
Cole J, Sohn MN, Harris AD, Bray SL, Patten SB, McGirr A (December 2022). "Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder: A Randomized Clinical Trial". JAMA Psychiatry. 79 (12): 1153–1161. doi:10.1001/jamapsychiatry.2022.3255. PMC 9557938. PMID 36223114.

ncbi.nlm.nih.gov

Sapko MT, Manyak M, Panicucci R, Javitt JC (March 2024). "NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro". Antibiotics. 13 (4). National Institutes of Health: 308. doi:10.3390/antibiotics13040308. PMC 11047644. PMID 38666984.
Lambert MP, Neuhaus FC (June 1972). "Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W". Journal of Bacteriology. 110 (3): 978–987. doi:10.1128/JB.110.3.978-987.1972. PMC 247518. PMID 4555420.
Schade S, Paulus W (April 2016). "D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review". The International Journal of Neuropsychopharmacology. 19 (4) pyv102. doi:10.1093/ijnp/pyv102. PMC 4851259. PMID 26364274.
Uda N, Matoba Y, Kumagai T, Oda K, Noda M, Sugiyama M (June 2013). "Establishment of an in vitro D-cycloserine-synthesizing system by using O-ureido-L-serine synthase and D-cycloserine synthetase found in the biosynthetic pathway". Antimicrobial Agents and Chemotherapy. 57 (6): 2603–2612. doi:10.1128/AAC.02291-12. PMC 3716191. PMID 23529730.
Ori R, Amos T, Bergman H, Soares-Weiser K, Ipser JC, Stein DJ (May 2015). "Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders". The Cochrane Database of Systematic Reviews. 2015 (5) CD007803. doi:10.1002/14651858.CD007803.pub2. PMC 8939046. PMID 25957940.
Myers KM, Carlezon WA (June 2012). "D-cycloserine effects on extinction of conditioned responses to drug-related cues". Biological Psychiatry. 71 (11): 947–955. doi:10.1016/j.biopsych.2012.02.030. PMC 4001849. PMID 22579305.
Cole J, Sohn MN, Harris AD, Bray SL, Patten SB, McGirr A (December 2022). "Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder: A Randomized Clinical Trial". JAMA Psychiatry. 79 (12): 1153–1161. doi:10.1001/jamapsychiatry.2022.3255. PMC 9557938. PMID 36223114.

toxnet.nlm.nih.gov

"CYCLOSERINE: Human Health Effects". National Institutes of Health. Archived from the original on 2014-04-16.

ods.od.nih.gov

"Vitamin B6 Fact Sheet for Health Professionals". Office of Dietary Supplements. National Institutes of Health. Retrieved 24 May 2026.

nytimes.com (Global: 7^th place; English: 7^th place)

Pollack A (20 September 2015). "Drug Goes From $13.50 a Tablet to $750, Overnight". The New York Times. Archived from the original on 25 September 2015. Retrieved 21 September 2015.
Pollack A (21 September 2015). "Big Price Increase for Tuberculosis Drug Is Rescinded". NYT. Archived from the original on 26 September 2015. Retrieved 24 September 2015.

openlibrary.org (Global: 185^th place; English: 154^th place)

Brimblecombe RW, Pinder RM (1975). "Miscellaneous Hallucinogens". Hallucinogenic Agents. Bristol: Wright-Scientechnica. pp. 196–216. ISBN 978-0-85608-011-1. OCLC 2176880. OL 4850660M. However, the closely related antibiotic oxamycin [(d-cycloserine)] (7.6) produces mental confusion, acute psychotic episodes, convulsions, and other abnormal behavioural states in man reminiscent of the isoxazoles [like muscimol and ibotenic acid] contained in Amanita muscaria (Farnsworth, 1968).

patents.google.com (Global: 1,154^th place; English: 606^th place)

Harned RL (21 May 1963). "US3090730A Process for the production of cycloserine". Google Patents.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Prosser GA, de Carvalho LP (February 2013). "Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine". The FEBS Journal. 280 (4): 1150–1166. doi:10.1111/febs.12108. PMID 23286234. S2CID 22305408.
Polc P, Pieri L, Bonetti EP, Scherschlicht R, Moehler H, Kettler R, et al. (April 1986). "L-cycloserine: behavioural and biochemical effects after single and repeated administration to mice, rats and cats". Neuropharmacology. 25 (4). Elsevier BV: 411–418. doi:10.1016/0028-3908(86)90236-4. PMID 3012401. S2CID 462885.

web.archive.org (Global: 1^st place; English: 1^st place)

"CYCLOSERINE: Human Health Effects". National Institutes of Health. Archived from the original on 2014-04-16.
Gottlieb D, Shaw PD (2012). Mechanism of Action. Springer Science & Business Media. p. 41. ISBN 978-3-642-46051-7. Archived from the original on 2016-12-20.
Pollack A (20 September 2015). "Drug Goes From $13.50 a Tablet to $750, Overnight". The New York Times. Archived from the original on 25 September 2015. Retrieved 21 September 2015.
Pollack A (21 September 2015). "Big Price Increase for Tuberculosis Drug Is Rescinded". NYT. Archived from the original on 26 September 2015. Retrieved 24 September 2015.

who.int (Global: 213^th place; English: 314^th place)

iris.who.int

"WHO consolidated guidelines on drug-resistant tuberculosis treatment". Institutional Repository for Information Sharing. World Health Organization. Retrieved 24 May 2026.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Brimblecombe RW, Pinder RM (1975). "Miscellaneous Hallucinogens". Hallucinogenic Agents. Bristol: Wright-Scientechnica. pp. 196–216. ISBN 978-0-85608-011-1. OCLC 2176880. OL 4850660M. However, the closely related antibiotic oxamycin [(d-cycloserine)] (7.6) produces mental confusion, acute psychotic episodes, convulsions, and other abnormal behavioural states in man reminiscent of the isoxazoles [like muscimol and ibotenic acid] contained in Amanita muscaria (Farnsworth, 1968).
Schultes RE, Farnsworth NR (1980). "Ethnomedical, Botanical and Phytochemical Aspects of Natural Hallucinogens". Botanical Museum leaflets, Harvard University. 28 (2): 123–214. doi:10.5962/p.168645. ISSN 0006-8098.

Cycloserine (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 529th place; English: 550th place)

hdl.handle.net (Global: 66th place; English: 34th place)

netfirms.com (Global: 9,451st place; English: 4,978th place)